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Effect of Antiretroviral Therapy on the Memory and
Activation Profiles of B Cells in HIV-Infected African Women
Ramla F. Tanko,* Andreia P. Soares,* Tracey L. M€uller,* Nigel J. Garrett,†
Natasha Samsunder,† Quarraisha Abdool Karim,†,‡ Salim S. Abdool Karim,†,‡
Catherine Riou,*,x,1 and Wendy A. Burgers*,x,1
Human immunodeficiency virus infection induces a wide range of effects in B cells, including skewed memory cell differentiation,
compromised B cell function, and hypergammaglobulinemia. However, data on the extent to which these B cell abnormalities can
be reversed by antiretroviral therapy (ART) are limited. To investigate the effect of ART on B cells, the activation (CD86) and dif-
ferentiation (IgD, CD27, and CD38) profiles of B cells were measured longitudinally in 19 HIV-infected individuals before (median, 2
mo) and after ART initiation (median, 12 mo) and compared with 19 age-matched HIV-uninfected individuals using flow cytometry.
Twelvemonths of ARTrestored the typical distribution of B cell subsets, increasing the proportion of naive B cells (CD272IgD+CD382)
and concomitantly decreasing the immature transitional (CD272IgD+CD38+), unswitched memory (CD27+IgD+CD382), switched
memory (CD27+IgD2CD382 or CD272IgD2CD382), and plasmablast (CD27+IgD2CD38high) subsets. However, B cell activation was
only partially normalized post-ART, with the frequency of activated B cells (CD86+CD40+) reduced compared with pre-ART levels
(p = 0.0001), but remaining significantly higher compared with HIV-uninfected individuals (p = 0.0001). Interestingly, unlike for
T cell activation profiles, the extent of B cell activation prior to ART did not correlate with HIV plasma viral load, but positively
associated with plasma sCD14 levels (p = 0.01, r = 0.58). Overall, ART partially normalizes the skewed B cell profiles induced by HIV,
with some activation persisting. Understanding the effects of HIV on B cell dysfunction and restoration following ART may provide
important insights into the mechanisms of HIV pathogenesis. The Journal of Immunology, 2017, 198: 1220–1228.
S
ystemic immune hyperactivation is a hallmark of HIV
infection, affecting a range of immune cells, including both
T cells and B cells (1). Multiple B cell defects have been
reported in HIV-infected individuals, including alteration in the dis-
tribution of B cell memory subsets, with the accumulation of dif-
ferentiated B cells (2–5), excessive B cell activation (6, 7), and
increased cell turnover (8). These B cell perturbations lead to func-
tional abnormalities, as demonstrated by hypergammaglobulinemia,
decreased B cell responsiveness to both T cell-dependent and T cell-
independent Ags (9–11), and compromised responses to vaccination
(9, 12, 13).
The specific mechanisms contributing to B cell abnormalities are
only partially known, and multiple factors may account for their
dysfunction. HIV-driven alteration of the cytokine and chemokine
environment has been described as a source of B cell dysfunction
(5, 14–16); and it has also been proposed that specific HIV pro-
teins may have a direct effect on B cells (17, 18). Several studies,
performed mostly in cross-sectional Caucasian cohorts, have in-
vestigated the effect of antiretroviral therapy (ART) on B cells,
reporting that suppressive ART can partially or completely nor-
malize B cell phenotypic defects, as shown by the replenishment
of naive B cells (19–22), contraction of activated B cells (21–25),
and increase in B cell survival potential (26). It is still uncertain,
however, whether normalization of B cell memory subsets results
in improved B cell immune responses to Ags, including influenza,
measles, pneumococcus, and hepatitis B (6, 10, 11, 27, 28).
There is a paucity of published studies on female and African
populations with regard to B cell activation and restoration of B cell
immunity following successful treatment of HIV (29, 30). There
are cogent reasons to believe there may be differences in African
compared with Caucasian cohorts. African cohorts have demon-
strated higher baseline levels of T cell activation, significantly
different T cell memory differentiation profiles (31, 32), and
consistently weaker cellular and humoral reactivity to some vac-
cines (33, 34). A variety of factors may influence immune acti-
vation and therefore normalization of immune profiles after ART,
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such as genetic, gender, and environmental differences, the latter
including higher antigenic exposure, diet, and gut microbiota.
Furthermore, a variety of sex-specific differences in the response
to infections have been described. Women have higher levels of
immune activation and faster progression of HIV disease than men
with the same viral load (35). These effects have been attributed to
estrogen receptor signaling and/or differences in expression of key
X-chromosome-expressed immune regulators, such as TLR and
CD40L (36). Additional factors such as HIV strains, treatment
regimens, and delayed access to HIV treatment could result in
distinct outcomes with respect to immunity after ART.
Thus, in this study, to define the extent to which ART restores the
B cell phenotype, we measured the memory differentiation and
activation profiles of B cells longitudinally in chronically HIV-
infected African women before and 12 mo after ART initiation,
and compared these profiles to age- and sex-matched HIV-
uninfected individuals.
Materials and Methods
Description of study participants
Study participants consisted of 19 women from the Centre for the AIDS
Program of Research in South Africa (CAPRISA) 002 HIV acute infection
cohort in KwaZulu-Natal, as previously described (37, 38). Peripheral
blood samples were obtained at two time points, during chronic infection
pre-ART initiation, and post-ART initiation. With respect to ART regi-
mens, 15 of the 19 participants were taking current standard first-line
therapy (TDF/3TC/EFV or TDF/FTC/EFV), and four took one of D4T/
3TC/EFV, D4T/3TC/NVP, AZT/3TC/NVP, or AZT/3TC/LPV/r. One par-
ticipant (CAP255) switched ART regimens during the study period (D4T/
3TC/EFV to AZT/3TC/EFV at month 10). No participants had active tu-
berculosis during the study period, or exhibited any immune reconstitution
inflammatory syndrome upon HIV treatment. An additional 19 HIV-
uninfected women who were matched for age and ethnicity were stud-
ied, from the CAPRISA 004 1% tenofovir microbicide gel trial (39). These
women were either in the preintervention or placebo arm of the trial. For
HIV-infected individuals, either a prospective RNA positive/Ab negative
reading or the midpoint between the last Ab negative test and the first Ab
positive ELISA test were used to determine the time postinfection. Highly
active ART was given according to the South African national HIV
treatment guidelines (at a CD4 count of ,200 cells/mm3 prior to October
2012; ,350 cells/mm3 until March 2015). Ethical approval for the study
was obtained from the Research Ethics Committees at the University of
KwaZulu-Natal and the University of Cape Town. All participants pro-
vided written informed consent prior to participating in the study.
Measurements of HIV plasma viral load and CD4 counts
Plasma HIV viral load and CD4 count were assessed at each study visit. Over
the course of the study, the viral load PCR assay switched from Roche
AMPLICOR HIV-1 monitor test version 1.5 (lower detection limit [LDL] of
400 RNA copies/ml) to Roche Taqmanversion 1.0 in June 2010 (LDL 40 RNA
copies/ml), and then to Roche Taqman version 2.0 in January 2012 (LDL 20
RNA copies/ml). The FACSCalibur TruCOUNT method (BD Biosciences)
was used to measure blood absolute CD4+ and CD8+ T cell counts.
Sample processing
PBMC were isolated by Ficoll-Hypaque (Amersham Pharmacia) density
gradient centrifugation and cryopreserved in freezing media (heat-
inactivated FCS; Invitrogen) containing 10% DMSO (Sigma-Aldrich).
Cells were stored in liquid nitrogen until use. Cryopreserved PBMC
were thawed and rested in R10 (RPMI 1640 plus 10% heat-inactivated FCS
and 50 U/ml of penicillin-streptomycin) at 37˚C with 5% CO2 for 3 h
before staining.
Abs, surface, and intracellular staining
The following Abs were used in three different staining panels: CD19 ECD
(J3-119), CD27 PE-Cy5 (1A4CD27; both Beckman Coulter), IgDAPC-Cy7
(IA6-2), CD10 BV605 (HI10a), CD21 PE-Cy7 (Bu32), CD40 PerCP-Cy5.5
(5C3; all BioLegend), CD38 APC (HIT2), CD86 PE (IT2.2), CD3 PE-Cy7
(SK7), HLA-DR APC-Cy7 (L243; all BD Biosciences), CD4 PE-Cy5.5
(S3.5), CD8 Qdot-705 (3B5), CD19 Pacific Blue (SJ25-CI), CD14 Pa-
cific Blue (T€uk4), CD3 Pacific Blue (UCHT1), Ki67 FITC (7B11; all
Invitrogen), and a violet viability reactive dye (Vivid; Molecular Probes).
All Abs were titrated prior to use to obtain optimal titers for staining.
Briefly, PBMC were stained with Vivid, then labeled with Abs against
surface markers, fixed, permeabilized, and subsequently stained intracel-
lularly with Ki67. Cells were then resuspended in 13 CellFix (BD Bio-
sciences) and kept at 4˚C until acquisition. Samples were acquired on a BD
Fortessa using FACSDiva software and analyzed using FlowJo (version
9.9.3; TreeStar). The gating strategy to identify B cell subsets is shown in
Supplemental Fig. 1.
ELISAs
Plasma samples were used to measure soluble CD14 (sCD14; a marker of
monocyte/macrophage activation) from the same women pre- and post-
ART. One participant was not included in this analysis due to the sam-
ple being unavailable. Plasma (n = 18) was tested in duplicate using
commercially available ELISA kits according to the manufacturer’s pro-
tocol (R&D Systems). In addition, 30 plasma samples from HIV-
uninfected women from the same cohort were included. Samples were
diluted 1:200, data were collected using a SpectraMax Plus reader (Mo-
lecular Devices), and point-to-point curve fits were used to calculate
sCD14 concentrations from the standard curves. Data were analyzed using
SoftMax Pro software (Version 3.2.1; Molecular Devices).
Statistical analyses
Statistical analyses were performed using GraphPad Prism (version 5.0).
The Mann–Whitney U test and the Wilcoxon Signed Rank test were used
for unmatched and paired samples, respectively. Correlations between the
different groups were determined by the non-parametric Spearman Rank
test. A p value ,0.05 was considered statistically significant.
Results
Effect of ART on the memory differentiation and activation of
B cells
To define the extent to which ART normalizes HIV-induced alter-
ation of B cells, we first determined the distribution of B cell subsets
in 19 HIV-infected individuals before and 1 y after ART initiation,
and compared it to 19 HIV-uninfected matched controls. Pre-ART
samples were obtained during chronic infection at a median of
4.9 y (interquartile range [IQR]: 2.8–5.8 y) after the estimated date
of HIV infection, and a median of 1.5 mo (IQR: 0.05–2.7) prior to
starting ART. The median plasma viral load at this time was 34,325
HIV RNA copies/ml (IQR: 7,997–78,573), and the median CD4
count was 314 cells/mm3 (IQR: 260–369) (Table I). After a median
of 12 mo of treatment (IQR: 12–13 mo), all individuals exhibited
viral suppression (p = 0.0001), the majority to ,40 copies/ml, and
an increase in both absolute CD4 count and CD4/CD8 ratio (both
p = 0.0001) (Table I, data not shown).
Fig. 1A shows representative flow plots of each B cell subset
from one HIV-uninfected and one HIV-infected individual pre-
and post-ART. Based on the expression of CD27, IgD, and CD38,
six B cell subsets were identified, namely immature transitional
B cells (CD272IgD+CD38+), naive B cells (CD272IgD+CD382),
unswitched memory (CD27+IgD+CD382), CD27+ switched
memory B cells (IgD2CD382), CD272 switched memory B cells
(IgD2CD382), and plasmablasts (CD27+IgD2CD38high). There
was a marked skewing of B cell subsets in chronic HIV infection
prior to ART (Fig. 1B). When compared with HIV-uninfected
participants, HIV-infected individuals were characterized by sig-
nificantly higher frequencies of immature transitional B cells,
unswitched memory B cells, and plasmablasts (median: 9.3%
[IQR: 6.3–13.3] versus 14.8% [IQR: 10.6–20]; 1.5% [IQR: 1.2–
1.7] versus 2.3% [IQR: 2–5.8] and 0.44% [IQR: 0.3–1] versus
2.1% [IQR: 1.4–4], respectively), and significantly lower propor-
tions of naive B cells (median: 65.8% [IQR: 60–72.1] versus
46.9% [IQR: 39.7–55.7]) (Fig. 1B). Additionally, the frequencies
of switched memory B cells expressing CD27 or not were com-
parable in HIV-uninfected and ART naive HIV-infected individuals
The Journal of Immunology 1221











(∼8 and ∼12%, respectively). It is worth mentioning that the
frequency of unswitched memory B cells in our healthy study
population was ∼7 times lower when compared with a previous
study reporting that the proportion of unswitched memory was
comparable to switched memory (representing ∼15% of total
B cells) in a predominantly male cohort from London (11). Fol-
lowing 12 mo of ART, the frequency of immature transitional,
naive and unswitched memory B cells were normalized, returning
to levels comparable to those observed in HIV-uninfected indi-
viduals (Fig. 1B). The frequency of plasmablasts was also reduced
in response to ART (p = 0.004), but remained significantly ele-
vated compared with the HIV-uninfected group. To further define
the restoration dynamics of B cell subsets upon ART, we com-
pared the fold change in their frequencies pre- and post-ART.
After 1 y of ART, only naive B cells displayed an overall ex-
pansion (median 1.3 fold [IQR: 1.2–1.5]); among the subsets
decreasing upon ART, plasmablasts exhibited the largest con-
traction, with a median fold change of 0.38 (IQR: 0.22–0.72). The
contraction of other B cells subsets was more moderate with a
median fold change of 0.51 (IQR: 0.39–0.92) for unswitched
memory B cells, 0.65 (IQR: 0.37–0.77) for immature transitional
B cells, 0.79 (IQR: 0.5–1) for CD27+ switched memory B cells
and 0.87 (IQR: 0.69–1) CD272 switched memory B cells
(Fig. 1C). Although ART had a predominant effect on reducing
the frequency of plasmablasts (∼60% reduction), this was not
sufficient for their normalization with respect to HIV-uninfected
individuals.
Alternative B cell markers such as CD27, CD10, and CD21 have
been used to delineate B cell memory subsets (40), allowing for the
identification of three additional B cell memory subsets, namely
tissue-like memory (CD102CD212CD272), resting memory
(CD21+CD27dim), and activated memory (CD102CD212
CD27dim) B cells (Supplemental Fig. 1B). The expression of
CD10 and CD21 on B cell subsets is shown in Supplemental Fig.
2. Thus, to validate our data, we defined the evolution of B cell
memory subpopulations pre- and post-ART using this set of
markers in 10 of the HIV-infected individuals from our study
(Supplemental Fig. 3). ART led to a significant reduction in the
frequencies of tissue-like memory, activated memory B cells, and
plasmablasts, and an increase in the frequencies of naive and
resting memory B cells. These observations confirm the data de-
scribed above, and are in line with published data (21). Of note,
using this alternative gating strategy, we found no significant
difference in the frequencies of immature transitional B cells
between the two time points. This may be due to the small sam-
ple size (a subset of n = 10) used for this set of markers, because
further analysis of the same individuals using IgD, CD38, and
CD27 also showed no significant difference in immature transi-
tional B cells (data not shown).
The effects of ART on B cell activation and proliferation were
also evaluated. Fig. 2A shows representative flow plots of B cell
activation, measured as the frequency of B cells coexpressing
CD86 and CD40, and proliferation (Ki67 expression) from one
HIV-uninfected and one HIV-infected individual pre- and post-
ART. The frequency of activated B cells (CD86+CD40+) was
significantly higher in HIV-infected subjects prior to ART com-
pared with HIV-uninfected participants (median: 14% [IQR: 9.2–
15.6] versus 1.7% [IQR: 1.3–2.3]; Fig. 2B). In response to ART,
the frequency of activated B cells was substantially reduced but
remained significantly higher than in HIV-uninfected participants
(Fig. 2B). It is important to mention that during HIV infection,
activated B cells were mostly confined to switched memory cells
(i.e., IgD2 B cells), with a median of 25% (IQR: 19.6–32) of
switched cells coexpressing CD40 and CD86. On the contrary, the
activation level of unswitched B cells (i.e., IgD+ B cells) was only
marginal, with less than 5% of these cells positive for CD40 and
CD86 (median: 4.5% [IQR: 2.4–5]; data not shown).
Similar to activated B cells, there were significantly more Ki67+
B cells in ART-naive HIV-infected individuals compared with
HIV-uninfected controls (median: 5% [IQR: 2.9–7.2] versus 1.3%
[IQR: 0.9–1.6]) and although ART led to a significant decline in
proliferating B cells, they remained elevated compared with the
HIV-uninfected group (p = 0.001, Fig. 2C). Of note, the fre-
quencies of proliferating (Ki67+) and activated (CD86+CD40+)
B cells were positively associated with the frequency of plasma-
blasts following ART (p = 0.004, r = 0.62 and p = 0.003, r = 0.63,
respectively, data not shown), suggesting that residual B cell ac-
tivation and proliferation upon ART may be explained by the
persistence of an elevated frequency of plasmablasts, consistent
with our findings presented in Fig. 1B.
Overall, our data show that HIV infection skews the B cell
memory differentiation profile and causes abnormal B cell acti-
vation and proliferation. Defects in B cell memory phenotype were
largely normalized within 1 y of ART, whereas B cell activation and
proliferative capacities were only partially reduced and longer
periods of suppressive therapy may be required for normalization.
B cell defects during HIV infection do not directly associate
with HIV viral load
It has been clearly established that hyper-immune activation of
T cells during HIV infection is related to viral replication (41) and
is partially normalized upon ART (42). This was confirmed in our
experimental setting, where we had T cell activation data for 18 of
the participants in the current study, as well as 14 additional
subjects from the same cohort. The proportion of activated CD4+
T cells (measured by the expression of HLA-DR) was positively
associated with plasma viral load (p = 0.001, r = 0.54; Fig. 3A) in
HIV-infected subjects pre-ART. Although 12 mo of ART led to a
substantial reduction in the frequency of HLA-DR expression by
T cells, T cell activation levels remained significantly higher than
in HIV-uninfected subjects (Supplemental Fig. 4). Thus, to de-
termine whether HIV load was also the driving factor for B cell
activation, we examined the relationship between B cell phenotype
and HIV plasma viral load before ART initiation. As previously
Table I. Clinical parameters of study participants
HIV-Infected HIV-Infected
p Value(Pre-ART) (Post-ART)
Sample size 19 19 (paired)
CD4 count (cells/mm3)a 314 (260–369) 629 (514–696) p = 0.0001
CD4/CD8 ratioa 0.23 (0.18–0.33) 0.61 (0.48–0.74) p = 0.0001
Viral load (RNA copies/ml)a 34,325 (7,997–78,573) ,20 (,20–39) p = 0.0001
Duration of ART (months)a NA 12 (12–13)
aMedian and interquartile range.
NA, not applicable.
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stated, switched memory B cells (i.e., IgD2 B cells) are highly
activated during HIV infection, thus we focused our analyses on this
particular subset. Surprisingly, unlike for T cells, we found no as-
sociation between the frequency of activated (CD86+CD40+)
switched memory B cells and HIV viral load (p = 0.71, r = 0.39;
Fig. 3B). Moreover, none of the B cell memory subset frequencies
were found to be associated with viral load (data not shown). Finally,
the extent of CD4+ or CD8+ T cell activation did not correlate with
the level of switched B cell activation (p = 0.78, r = 0.07; Fig. 3C,
data not shown). Together, these results show that HIV differentially
affects the T cell and B cell compartments, where B cell activation
does not mirror T cell activation and is not directly associated with
the levels of HIV. This suggests that additional factors besides HIV
replication may contribute to B cell activation.
FIGURE 1. Effect of ART on the memory differentiation profile of B cells. (A) Representative flow plots of CD27, IgD, and CD38 expression in B cells
from one HIV-uninfected and one HIV-infected (pre- and post-ART) individual. Numbers represent the frequencies of each B cell subset, namely immature
transitional (CD272IgD+CD38+), naive (CD272IgD+CD382), Unswitched memory (CD27+IgD+CD382), switched CD27+ memory (IgD2CD382),
switched CD272 memory (IgD2CD382), and plasmablasts (CD27+IgD2CD38high). (B) Frequencies of B cell subsets in HIV-uninfected (n = 19; open
circles) and HIV-infected pre- and post ART (n = 19; closed circles) individuals. Horizontal lines indicate the median. Statistical significance was calculated
using a Mann–Whitney U test and Wilcoxon Signed Rank for unpaired and paired samples, respectively. (C) Fold change in the frequency of B cell subsets
over 12 mo of ART. Data are shown as box and whisker (interquartile range) plots. The vertical dotted line indicates no change from the time point prior to
ART. Statistical comparisons were calculated using a one-way ANOVA test. *p , 0.05, **p , 0.01, ***p , 0.001.
The Journal of Immunology 1223











Additional contributors of B cell defects during HIV infection
The translocation of bacterial products resulting from HIV-induced
damage to the gastrointestinal tract is an important contributor of
systemic immune activation (43). Therefore, we investigated the
relationship between the activation and skewed differentiation
profile of B cells and the level of plasma sCD14, a marker of
monocyte/macrophage activation, which may be an indicator, in
the absence of other infections, of microbial translocation. Prior to
ART, plasma sCD14 levels associated negatively with the fre-
quency of naive B cells (p = 0.036, r = 20.50; data not shown)
and positively with the frequency of immature transitional B cells
(p = 0.003, r = 0.75; Fig. 4A), and the frequency of activated
(CD86+CD40+) switched memory B cells (p = 0.01, r = 0.58;
Fig. 4B). Moreover, a positive correlation was also observed
between sCD14 levels and the frequency of activated HLA-DR+
CD4+ T cells (p = 0.045, r = 0.49; Fig. 4C). It is worth noting that
the levels of plasma sCD14 were not significantly changed after
12 mo of ART (Supplemental Fig. 5), and there were no associ-
ations with residual B cell activation post-ART (data not shown).
Overall, these data suggest a possible impact of microbial
translocation on B cell dysfunction, as suggested by sCD14 levels
correlating with HIV-induced B cell skewing and hyperactivation in
untreated chronic HIV infection. However, their influence may be
relatively minor, because there are consistently elevated levels of
sCD14 after ART, when B cell defects are largely reversed. It is
clear that a variety of factors may directly or indirectly influence
B cell defects during HIV infection.
Discussion
Despite the fact that HIV does not directly infect B cells, the virus
causes several B cell abnormalities that contribute to HIV path-
ogenesis (44). Although these B cell defects may be reverted upon
ART, this effect has mostly been studied in cross-sectional Cau-
casian cohorts. Thus, in this study we assessed longitudinally the
impact of ART on the memory and activation profile of B cells in
South African adult women (n = 19); and compared these profiles
to age-matched HIV-uninfected women from the same community
(n = 19). Our data show that: 1) HIV-induced alterations of B cells
did not associate with viral burden but rather correlated with
plasma sCD14 concentration; and 2) 12 mo of ART largely nor-
malized the distribution of B cell memory subsets whereas acti-
vation of B cells was only partially reduced.
HIV induces multiple defects in B cells, altering their memory
and activation profiles and function (3, 5, 40, 45). In our experi-
mental setting, we showed that in HIV-infected African women
B cells were skewed toward a more differentiated memory phe-
notype (with the accumulation of plasmablasts and the reduction
of naive B cells) and were hyperactivated (as measured by CD86
expression) when compared with HIV-uninfected persons. These
observations are in accordance with previous studies performed
primarily in male Caucasian populations (3, 20, 21, 6, 45, 46),
highlighting that similar abnormalities occur in African women.
To date, the drivers of B cell alterations during HIV infection have
not been fully elucidated. Even though HIV does not directly
target B cells for infection, the interaction between HIV and
B cells has been previously described, where HIV gp120 can bind
to B cell receptors such as CD21, DC-SIGN, and variable H chain
3 (VH3) Ig, resulting in polyclonal B cell activation and Ig pro-
duction (47). Furthermore, HIV Nef can interact directly with
B cells, resulting in suppression of Ig class switching (48, 49).
How each of these mechanisms contributes to B cell dysfunction
is unknown (40).
It has also been proposed that excessive B cell activation may
be driven by proinflammatory cytokines, such as IFN-a, TNF-a,
IL-6, and IL-10, molecules commonly up-regulated during HIV-
induced systemic inflammation (50). HIV infection also leads to
increased production of B cell-specific growth factors such as
BLyS/BAFF from macrophages, dendritic cells, and gran-
ulocytes (51–53), promoting B cell dysregulation right from the
early stages of infection. Additionally, HIV pathogenesis has
also been linked to extensive damage to the gastrointestinal tract,
leading to the release of bacterial products into the circulation
(43). These products may induce aberrant B cell activation via
TLR signaling (54), by both direct and indirect means. Stimu-
lation of monocytes by bacterial LPS leads to the release of
cytokines that contribute to the inflammatory environment. Ad-
ditionally, human B cells express a range of TLRs, including
high levels of TLR9 (55), and abundant bacterial DNA as a result
of HIV-induced microbial translocation (56) may stimulate
B cells directly. In fact, TLR9 stimulation of human B cells
promotes their activation, proliferation, and the generation of
FIGURE 2. Effect of ART on B cell activation and proliferation. (A)
Representative flow plots of CD40, CD86, and Ki67 expression in B cells
from one HIV-uninfected and one HIV-infected (pre- and post-ART) in-
dividual. Numbers represent the frequencies of activated (CD86+CD40+)
and proliferating (Ki67+) B cells. (B) Frequencies of CD86+CD40+ B cells
in HIV-uninfected (n = 19; open circles) and HIV-infected pre- and post-
ART (n = 19; closed circles) individuals. (C) Frequencies of proliferating B
cells as measured by Ki67 expression. Horizontal lines represent the me-
dian. Statistical significance was calculated using a Mann–Whitney U test
and Wilcoxon Signed Rank for unpaired and paired samples, respectively.
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plasmablasts (57, 58). The potential role of microbial products as
direct factors fueling B cell hyperactivation is further inferred by
the fact that in other chronic diseases leading to gut damage
(such as inflammatory bowel disease), B cells exhibit aberrant
activation profiles (59).
We found an association pre-ART of B cell activation and dif-
ferentiation profile with the concentration of plasma sCD14, se-
creted upon monocyte/macrophage activation by LPS, which may
be a surrogate marker of microbial translocation. Interestingly,
although there was a relative normalization of B cells post-ART,
plasma sCD14 concentration did not decrease overall upon treat-
ment. This phenomenon has been observed in several studies,
where sCD14 levels remain elevated even after several years on
ART (60–62), and unreversed damage to the gastrointestinal tract
has been proposed to account for this. These data confirm that in
African women, inflammation persists after ART even when there
is a substantial decrease in cellular activation. The absence of any
decrease in sCD14 after ART, despite a substantial normalization
of B cell profiles, suggests that sCD14 plays only a partial role in
contributing to B cell activation. Alternatively, we could speculate
that microbial translocation and viral-induced factors might act
synergistically to drive B cell activation and skewing, and ART
uncouples this effect by suppressing viral replication even in the
face of ongoing inflammation. Although we did not find an as-
sociation of HIV viral load with B cell dysfunction pre-ART, this
relationship may not be linear, with a multitude of viral-induced
factors influencing B cell activation and differentiation directly
and indirectly (63). Overall, this suggests that a combination of
inflammatory mediators such as cytokines, B cell growth factors,
and microbial products may directly and indirectly stimulate
B cell differentiation and proliferation, favoring their functional
impairment and exhaustion.
Several studies have shown that ART leads to a near normali-
zation of peripheral B cell memory subsets (19, 20, 22, 64); and the
extent of restoration was linked to the timing of ART initiation
(21, 65), the duration of treatment, or the age of the patients (22,
66). Very limited data are available on the effects of ART on
B cells in African cohorts. To our knowledge, only one cross-
sectional study has investigated how ART influences the restora-
tion of B cell numbers in an African adult population (30). In
countries disproportionately affected by the HIV pandemic and
where access to ART is limited and often started during advanced
lymphopenia, it is of importance to define whether HIV treatment
can restore B cell profiles to similar levels observed in HIV-
uninfected individuals (of note, the CD4 count pretreatment in
the participants included in this study was ,350 cells/mm3). Our
data showed that although 12 mo of ART largely normalized the
distribution of memory subsets, B cell activation remained sig-
nificantly elevated compared with HIV-uninfected individuals.
The persistence of these cycling, activated B cells composed
mainly of plasmablasts could reflect residual systemic inflamma-
tion, despite viral suppression. Indeed, it has been shown that even
upon successful ART, inflammation, microbial translocation, and
germinal center destruction still persist (43, 67–69). These ob-
servations are in line with results reported in Caucasian cohorts
(20, 21, 70), showing that the normalization of B cell subsets can
be achieved even when treatment is initiated at a late stage of
chronic HIV infection.
The limitations of this study include a cohort exclusively
composed of women; further studies could test the generalizability
of our findings in men. Additionally, we only analyzed B cells from
peripheral blood and this may not be representative of B cell
profiles within the tissues; it is plausible that B cells residing in
the germinal center are differentially affected during HIV infection
and that the extent and/or kinetics of their restoration during
treatment may differ. For future studies, use of additional phe-
notypic markers such as CD10 and CD24 could improve the
FIGURE 3. Relationship between CD4+ T cell and B cell activation and
plasma viral load pre-ART. Correlation of (A) the frequency of HLA-DR
expressing CD4+ T cells (n = 32) and (B) the frequency of CD40+CD86+
switched memory B cells (n = 19) and plasma viral load in HIV-infected
individuals prior to ART initiation. (C) Correlation between B cell acti-
vation (CD86+CD40+) and CD4+ T cell activation (HLA-DR+) in 18 HIV-
infected participants before ART. Statistical significance was calculated
using a non-parametric Spearman Rank test.
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definition of B cell subsets, in particular immature transitional
B cells. Furthermore, we did not examine the relationship of
relative normalization of B cell activation and differentiation with
restoration of functional B cell immunity, which may not always
return (71). Further studies of humoral immunity after ART are
warranted in larger African cohorts, by investigation of both
memory B cell responses and long-lived plasma cells to a variety
of vaccines and infections. This is particularly important if func-
tional B cell immunity is not fully restored and revaccination to
certain pathogens may be required. In this respect, early ART
initiation, compared with those treated during chronic HIV in-
fection, has demonstrated a benefit for restoration of B cell
functionality (21).
In conclusion, our study has shown that the B cell compartment
is highly disturbed in chronically HIV-infected African women, an
understudied group disproportionately affected by the HIV pan-
demic, as it is for Caucasian cohorts. Differences in methodology
limit our ability to directly compare our results in African women to
published studies in western cohorts, but we observed a substantial
reduction in B cell activation and a relative normalization of
skewed B cell subsets as observed in Caucasian cohorts, despite the
commencement of ART in chronic HIV infection. Identifying the
drivers of B cell activation and defective differentiation may
provide a better understanding of the mechanisms associated with
B cell dysfunction. This can potentially lead to the development of
intervention strategies to improve B cell function during HIV in-
fection, for both HIV-specific humoral immunity and responses to
vaccines targeting other pathogens.
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